(0.03%) 5 471.09 points
(0.08%) 39 145 points
(0.35%) 17 780 points
(-0.01%) $80.82
(-3.66%) $2.66
(-0.80%) $2 312.10
(0.18%) $28.92
(3.49%) $1 020.80
(0.27%) $0.936
(0.68%) $10.68
(0.42%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder...
Stats | |
---|---|
今日成交量 | 163 225 |
平均成交量 | 227 217 |
市值 | 4.19M |
EPS | $-0.600 ( Q1 | 2024-05-08 ) |
下一个收益日期 | ( $0 ) 2024-08-12 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.0300 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0120 (2.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-12 | Werth Peter J. | Buy | 10 000 | Stock Option (right to Buy) |
2024-06-11 | Werth Peter J. | Buy | 6 926 | Stock Option (right to Buy) |
2024-06-11 | Brams Matthew | Buy | 63 324 | Stock Option (right to Buy) |
2024-06-11 | Schaffer Shane J. | Buy | 217 677 | Stock Option (right to Buy) |
2024-06-11 | Callahan Jennifer L. | Buy | 94 986 | Stock Option (right to Buy) |
INSIDER POWER |
---|
78.37 |
Last 96 transactions |
Buy: 12 045 040 | Sell: 1 062 040 |
音量 相关性
Cingulate Inc. 相关性 - 货币/商品
Cingulate Inc. 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-582 918 (0.00 %) |
EPS: | $-26.01 |
FY | 2023 |
营收: | $0 |
毛利润: | $-582 918 (0.00 %) |
EPS: | $-26.01 |
FY | 2022 |
营收: | $0 |
毛利润: | $-621 993 (0.00 %) |
EPS: | $-31.57 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.831 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Cingulate Inc.
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。